Elisabeth I Heath

List of Publications by Year
in descending order

129 papers	7,873 citations	136740 32 h-index	54797 84 g-index
131 all docs	131 docs citations	131 times ranked	11482 citing authors

#	Article	IF	Citations
1	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 388-396.	2.0	15
2	Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumors. Investigational New Drugs, 2022, 40, 300-307.	1.2	4
3	Development and pilot test of a physician-focused cancer clinical trials communication training intervention. PEC Innovation, 2022, 1, 100012.	0.3	3
4	Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2022, 28, 1549-1559.	3.2	24
5	Preliminary results of a phase 1 study of sea-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2022, 40, 559-559.	0.8	5
6	Alcohol dehydrogenase expression patterns in normal prostate, benign prostatic hyperplasia, and prostatic adenocarcinoma in African American and Caucasian men. Prostate, 2022, , .	1.2	1
7	Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial. European Urology, 2022, 81, 515-522.	0.9	14
8	Targeting resistant prostate cancer, with or without DNA repair defects, using the combination of ceralasertib (ATR inhibitor) and olaparib (the TRAP trial).. Journal of Clinical Oncology, 2022, 40, 88-88.	0.8	10
9	Molecular alterations across sites of metastasis in patients with renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2022, 40, 287-287.	0.8	2
10	Comprehensive genomic profiling of penile squamous cell carcinoma and impact of HPV status on immune-checkpoint inhibition-related biomarkers.. Journal of Clinical Oncology, 2022, 40, 4-4.	0.8	2
11	Molecular and immune landscape of FH-mutated kidney cancer.. Journal of Clinical Oncology, 2022, 40, 382-382.	0.8	0
12	PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.. Journal of Clinical Oncology, 2022, 40, TPS191-TPS191.	0.8	1
13	Updated biomarker results from a phase 1/2 study of olaparib and radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases (COMRADE).. Journal of Clinical Oncology, 2022, 40, 119-119.	0.8	2
14	Phase 2 randomized trial of ModraDoc006/r, oral docetaxel plus ritonavir, versus intravenous docetaxel in metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, 117-117.	0.8	1
15	A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kî²/îˇ, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2022, 28, 2257-2269.	3.2	11
16	A pancancer analysis of impact of MDM2/MDM4 on immune checkpoint blockade (ICB).. Journal of Clinical Oncology, 2022, 40, 2630-2630.	0.8	2
17	Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, 3001-3001.	0.8	6
18	Genomic and immunologic profiles of concurrent RB1 and CDKN1A/p21(WAF1) truncating mutations (RW+) in bladder cancer.. Journal of Clinical Oncology, 2022, 40, 4571-4571.	0.8	0

#	Article	IF	Citations
19	PACCT: An intervention to improve communication quality and clinical trial invitations for Black and White men with prostate cancer.. Journal of Clinical Oncology, 2022, 40, e24137-e24137.	0.8	0
20	Phase II, double-blind, randomized study of salvage radiation therapy (SRT) plus enzalutamide or placebo for high-risk PSA-recurrent prostate cancer after radical prostatectomy: The SALV-ENZA Trial.. Journal of Clinical Oncology, 2022, 40, 5012-5012.	0.8	4
21	EVEREST: Everolimus for renal cancer ensuing surgical therapyâ€"A phase III study (SWOG S0931,) Tj ETQq1 1 0.784314 rgBT /Overlock	0.8	29
22	Outcomes with novel combinations in nonclear cell renal cell carcinoma (nccRCC): ORACLE study.. Journal of Clinical Oncology, 2022, 40, 4545-4545.	0.8	1
23	A phase 2 randomized study of oral docetaxel plus ritonavir (ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, 5016-5016.	0.8	0
24	Treatment Intensification Patterns and Utilization in Patients with Metastatic Castration-Sensitive Prostate Cancer. Clinical Genitourinary Cancer, 2022, 20, 524-532.	0.9	10
25	Landscape analysis of urothelial carcinoma (UC) by telomerase reverse transcriptase (TERT) alterations.. Journal of Clinical Oncology, 2022, 40, 4524-4524.	0.8	0
26	Characterization and impact of canonical Wnt Signaling Pathway (WSP) alterations on outcomes of metastatic prostate cancer.. Journal of Clinical Oncology, 2022, 40, 5053-5053.	0.8	0
27	Incorporation of intrapatient response heterogeneity using ¹⁸F-NaF PET/CT imaging improves outcome prediction models for metastatic prostate cancer patients.. Journal of Clinical Oncology, 2022, 40, e13554-e13554.	0.8	0
28	Molecular and immune landscape of FH-mutated cancers.. Journal of Clinical Oncology, 2022, 40, 3125-3125.	0.8	0
29	Molecular correlates of Delta-like-ligand 3 (DLL3) expression in neuroendocrine neoplasms (NENs).. Journal of Clinical Oncology, 2022, 40, 4127-4127.	0.8	1
30	The biology and rationale of targeting nectin-4 in urothelial carcinoma. Nature Reviews Urology, 2021, 18, 93-103.	1.9	89
31	Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type. Translational Oncology, 2021, 14, 101016.	1.7	22
32	Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry. JCO Global Oncology, 2021, 7, 495-505.	0.8	12
33	Lysine 53 Acetylation of Cytochrome c in Prostate Cancer: Warburg Metabolism and Evasion of Apoptosis. Cells, 2021, 10, 802.	1.8	17
34	Association of ATM mutations in metastatic prostate cancer with differential genomic alteration profiles from homologous recombination deficient and proficient tumors.. Journal of Clinical Oncology, 2021, 39, 5063-5063.	0.8	1
35	Differences in the tumor genomic landscape between African Americans (AA) and Caucasians (CA) advanced prostate cancer (aPC) patients (pts) by comprehensive genomic profiling (CGP) of cell-free DNA (cfDNA).. Journal of Clinical Oncology, 2021, 39, 5058-5058.	0.8	1
36	Phase I study of CCW702, a bispecific small molecule-antibody conjugate targeting PSMA and CD3 in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, TPS5094-TPS5094.	0.8	7

#	Article	IF	Citations
37	Discovery of primary prostate cancer biomarkers using cross cancer learning. Scientific Reports, 2021, 11, 10433.	1.6	19
38	Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells. International Journal of Molecular Sciences, 2021, 22, 6676.	1.8	5
39	Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EVâ€‘201): a multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2021, 22, 872-882.	5.1	122
40	A Phase 1 study Combining Pexidartinib, Radiation Therapy, and Androgen Deprivation Therapy in Men With Intermediate- and High-Risk Prostate Cancer. Advances in Radiation Oncology, 2021, 6, 100679.	0.6	3
41	Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer. Nature Cancer, 2021, 2, 978-993.	5.7	52
42	Symptom Outcomes of Cancer Patients With Clival Metastases Treated With Radiotherapy: A Study of 44 Patients. Anticancer Research, 2021, 41, 5001-5006.	0.5	3
43	Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types. Journal of Molecular Diagnostics, 2021, 23, 1761-1773.	1.2	2
44	Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer. JAMA Network Open, 2021, 4, e2034633.	2.8	29
45	eHealth Activity among African American and White Cancer Survivors: A New Application of Theory. Health Communication, 2020, 35, 350-355.	1.8	9
46	Unpacking Trial Offers and Low Accrual Rates: A Qualitative Analysis of Clinic Visits With Physicians and Patients Potentially Eligible for a Prostate Cancer Clinical Trial. JCO Oncology Practice, 2020, 16, e124-e131.	1.4	9
47	Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. JCO Oncology Practice, 2020, 16, 811-819.	1.4	35
48	A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. Clinical Cancer Research, 2020, 26, 5338-5347.	3.2	76
49	Exploring Spatial-Temporal Changes in ¹⁸F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide. Journal of Clinical Oncology, 2020, 38, 3662-3671.	0.8	16
50	Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1374-1380.	1.1	57
51	EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4â€“Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. Journal of Clinical Oncology, 2020, 38, 1041-1049.	0.8	159
52	Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. Prostate Cancer and Prostatic Diseases, 2020, 23, 517-526.	2.0	80
53	Detecting TRA-1â€“60 in Cancer via a Novel Zr-89 Labeled ImmunoPET Imaging Agent. Molecular Pharmaceutics, 2020, 17, 1139-1147.	2.3	6
54	Smartphone apps for cancer: A content analysis of the digital health marketplace. Digital Health, 2020, 6, 205520762090541.	0.9	47

#	Article	IF	Citations
55	An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer. Molecular Cancer Therapeutics, 2020, 19, 1373-1382.	1.9	20
56	Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. Journal of Clinical Oncology, 2019, 37, 2592-2600.	0.8	404
57	Prostate Tumor Cellâ€"Derived IL1Î² Induces an Inflammatory Phenotype in Bone Marrow Adipocytes and Reduces Sensitivity to Docetaxel via Lipolysis-Dependent Mechanisms. Molecular Cancer Research, 2019, 17, 2508-2521.	1.5	32
58	Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1â€"2 trial. Lancet Oncology, The, 2019, 20, 1432-1443.	5.1	115
59	A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). BMC Cancer, 2019, 19, 572.	1.1	3
60	Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Clinical Genitourinary Cancer, 2019, 17, 275-282.e1.	0.9	42
61	Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer. Oncologist, 2019, 24, 1149-e807.	1.9	9
62	The current state of molecular testing in the treatment of patients with solid tumors, 2019. Ca-A Cancer Journal for Clinicians, 2019, 69, 305-343.	157.7	203
63	Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11428-11436.	3.3	839
64	Prostate Cancer National Summitâ€™s Call to Action. Clinical Genitourinary Cancer, 2019, 17, 161-168.	0.9	0
65	Abstract CT095: A Phase Ib/IIa study of the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). Cancer Research, 2019, 79, CT095-CT095.	0.4	5
66	Interlesional response assessment with ¹⁸F-sodium fluoride (¹⁸F-NaF) PET/CT in men with chemotherapy-naive bone metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA).. Journal of Clinical Oncology, 2019, 37, 5036-5036.	0.8	0
67	Adipocyte-activated oxidative and ER stress pathways promote tumor survival in bone via upregulation of Heme Oxygenase 1 and Survivin. Scientific Reports, 2018, 8, 40.	1.6	32
68	Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, e695-e703.	0.9	12
69	Overexpression of the Pluripotent Stem Cell Marker Podocalyxin in Prostate Cancer. Anticancer Research, 2018, 38, 6361-6366.	0.5	18
70	Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review. Cancer and Metastasis Reviews, 2018, 37, 655-663.	2.7	18
71	Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors. Clinical Cancer Research, 2018, 24, 4072-4080.	3.2	25
72	Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell, 2018, 173, 1770-1782.e14.	13.5	400

#	Article	IF	Citations
73	Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression. Oncotarget, 2018, 9, 35327-35342.	0.8	11
74	Racial Disparities in the Molecular Landscape of Cancer. Anticancer Research, 2018, 38, 2235-2240.	0.5	32
75	Sample size determination for logistic regression on a logit-normal distribution. Statistical Methods in Medical Research, 2017, 26, 1237-1247.	0.7	10
76	Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, 463-471.	0.9	12
77	Percutaneous Cryoablation of Renal Tumors: Is It Time for a New ParadigmÂShift?. Journal of Vascular and Interventional Radiology, 2017, 28, 1363-1370.	0.2	46
78	Partnering around cancer clinical trials (PACCT): study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials. BMC Cancer, 2017, 17, 807.	1.1	26
79	Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy. , 2017, 5, 82.		77
80	Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update. Journal of Clinical Oncology, 2017, 35, 1737-1743.	0.8	128
81	Survival outcomes for African-American (AA) vs matched Caucasian (CAU) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (sip-T).. Journal of Clinical Oncology, 2017, 35, 192-192.	0.8	4
82	Neutrophil lymphocyte ratio (NLR) as a clinical biomarker predictive of outcomes with immune checkpoint inhibitor therapy in genitourinary cancers.. Journal of Clinical Oncology, 2017, 35, 453-453.	0.8	1
83	A clinical trial for the safety and immunogenicity of a DNA-based immunotherapy in men with biochemically (PSA) relapsed prostate cancer.. Journal of Clinical Oncology, 2017, 35, 80-80.	0.8	4
84	The influence of PSA autoantibodies in prostate cancer patients: a prospective clinical study-II. Oncotarget, 2017, 8, 17643-17650.	0.8	8
85	Immune evaluation study of sipuleucel-T (Sip-T) in African-American and European-American men with castration-resistant prostate cancer.. Journal of Clinical Oncology, 2017, 35, 206-206.	0.8	1
86	A phase II study of muscadine grape skin extract in men with biochemically recurrent prostate cancer.. Journal of Clinical Oncology, 2017, 35, 248-248.	0.8	1
87	Neutrophil lymphocyte ratio (NLR) as a predictor of outcomes with immune checkpoint inhibitor (ICI) therapy in genitourinary cancer and melanoma.. Journal of Clinical Oncology, 2017, 35, 37-37.	0.8	0
88	Development of a patient question prompt list to improve communication and clinical trial enrollment in a diverse patient population.. Journal of Clinical Oncology, 2017, 35, 143-143.	0.8	0
89	Positive associations between galectin-3 and PSA levels in prostate cancer patients: a prospective clinical study-I. Oncotarget, 2016, 7, 82266-82272.	0.8	18
90	Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells. Molecular Pharmacology, 2016, 90, 225-237.	1.0	18

#	Article	IF	Citations
91	Global peak alignment for comprehensive two-dimensional gas chromatography mass spectrometry using point matching algorithms. Journal of Bioinformatics and Computational Biology, 2016, 14, 1650032.	0.3	8
92	Radium-223 in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2016, 14, 373-380.e2.	0.9	22
93	Galectin-3 in bone tumor microenvironment: a beacon for individual skeletal metastasis management. Cancer and Metastasis Reviews, 2016, 35, 333-346.	2.7	23
94	Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis. Molecular Cancer, 2016, 15, 68.	7.9	89
95	Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients with Cancer. Cancer Control, 2016, 23, 327-337.	0.7	303
96	docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study. Investigational New Drugs, 2016, 34, 112-118.	1.2	46
97	Anti-androgenic activity of absorption-enhanced 3, 3'-diindolylmethane in prostatectomy patients. American Journal of Translational Research (discontinued), 2016, 8, 166-76.	0.0	6
98	Integrative Clinical Genomics of Advanced Prostate Cancer. Cell, 2015, 161, 1215-1228.	13.5	2,660
99	Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study. Urology, 2015, 86, 1206-1211.	0.5	34
100	Maspin Expression in Prostate Tumor Cells Averts Stemness and Stratifies Drug Sensitivity. Cancer Research, 2015, 75, 3970-3979.	0.4	25
101	Reply to G. Procopio et al. Journal of Clinical Oncology, 2014, 32, 3083-3084.	0.8	1
102	Preface. Cancer and Metastasis Reviews, 2014, 33, 375-376.	2.7	0
103	Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 31.e25-31.e33.	0.8	16
104	Maspin expression in prostate tumor elicits host anti-tumor immunity. Oncotarget, 2014, 5, 11225-11236.	0.8	22
105	A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2013, 71, 565-573.	1.1	40
106	A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors. Investigational New Drugs, 2012, 30, 1566-1574.	1.2	33
107	Efficacy and safety of pazopanib as a subsequent treatment after failure of other targeted agents in patients with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2012, 30, 415-415.	0.8	0
108	Reassessment of a proposed molecular classification system for clear cell renal cell cancer (ccRCC): Results from a randomized phase II trial of pazopanib.. Journal of Clinical Oncology, 2012, 30, 404-404.	0.8	0

#	Article	IF	Citations
109	Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults. Expert Opinion on Biological Therapy, 2011, 11, 1519-1524.	1.4	7
110	Apocrine Carcinoma of the Face in a 62-Year-Old Asian Man. Clinics and Practice, 2011, 1, 100-101.	0.6	5
111	A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies. Investigational New Drugs, 2011, 29, 1426-1431.	1.2	15
112	Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemotherapy and Pharmacology, 2011, 68, 703-712.	1.1	11
113	Theoretical and Practical Application of Traditional and Accelerated Titration Phase I Clinical Trial Designs: The Wayne State University Experience. Journal of Biopharmaceutical Statistics, 2009, 19, 414-423.	0.4	4
114	Modeling using baseline characteristics in a small multicenter clinical trial for Barrett's esophagus. Contemporary Clinical Trials, 2009, 30, 2-7.	0.8	9
115	A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Investigational New Drugs, 2008, 26, 59-65.	1.2	105
116	Quantitative endoscopy in the chemoprevention of Barrett's Esophagus Trial. Ecological Management and Restoration, 2008, 21, 641-644.	0.2	3
117	The Effect of Race/Ethnicity on the Accuracy of the 2001 Partin Tables for Predicting Pathologic Stage of Localized Prostate Cancer. Urology, 2008, 71, 151-155.	0.5	14
118	Malignant undifferentiated sex cord-stromal testis tumor with brain metastasis: Case report. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 53-55.	0.8	1
119	A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer. Clinical Cancer Research, 2008, 14, 7940-7946.	3.2	168
120	Targeted Therapy Trials for Prostate Cancer. , 2008, , 383-400.		0
121	Secondary Chemoprevention of Barrett's Esophagus With Celecoxib: Results of a Randomized Trial. Journal of the National Cancer Institute, 2007, 99, 545-557.	3.0	178
122	A Phase I Safety and Pharmacologic Study of a Twice Weekly Dosing Regimen of the Oral Taxane BMS-275183. Clinical Cancer Research, 2007, 13, 3906-3912.	3.2	26
123	New Targets in the Management of Prostate Cancer. Hematology/Oncology Clinics of North America, 2006, 20, 985-999.	0.9	1
124	Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Investigational New Drugs, 2006, 24, 135-140.	1.2	37
125	A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer. Clinical Prostate Cancer, 2005, 4, 138-141.	2.1	53
126	Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Investigational New Drugs, 2002, 20, 95-99.	1.2	53

#	Article	IF	Citations
127	Mutations in Î²-Catenin and APC Genes are Uncommon in Esophageal and Esophagogastric Junction Adenocarcinomas. Modern Pathology, 2000, 13, 1055-1059.	2.9	44
128	Phase II Evaluation of Preoperative Chemoradiation and Postoperative Adjuvant Chemotherapy for Squamous Cell and Adenocarcinoma of the Esophagus. Journal of Clinical Oncology, 2000, 18, 868-868.	0.8	126
129	Clinical Potential of Matrix Metalloprotease Inhibitors in Cancer Therapy. Drugs, 2000, 59, 1043-1055.	4.9	85